MedTrace Logo

Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis

NCT03568136 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2021-05-03

No results posted yet for this study

Summary

The overall aim of this study is to assess the effects of a new treatment called Secukinumab in adults suffering from moderate to severe atopic dermatitis. Furthermore, the study shall support the extension of the approval for Secukinumab from psoriasis to atopic dermatitis. The effectiveness of Secukinumab is determined on the reduction of the eczema score EASI 50 (Eczema Area and Severity Index, a tool to measure the severity of atopic dermatitis) at week 4.

Conditions

  • Dermatitis, Atopic
  • Eczema, Atopic
  • Neurodermatitis, Atopic

Interventions

DRUG

Secukinumab 300 mg

Solution for injection in pre-filled syringe

DRUG

Placebo

Solution for injection in pre-filled syringe

Sponsors & Collaborators

Principal Investigators

  • Stefan Beissert, Prof. Dr.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-18
Primary Completion
2020-05-04
Completion
2020-05-04

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03568136 on ClinicalTrials.gov